Zai Lab Limited (ZLAB) on Tuesday announced that China's National Medical Products Administration has given the green light to COBENFY for treating schizophrenia in adults.
Notably, it's the first new type of therapy for this condition in over 70 years. COBENFY works by targeting the M1 and M4 receptors in the brain, which gives patients another option besides the usual dopamine-based antipsychotics.
Zai Lab pointed out that this approval is a big step forward for the around 8 million adults in China living with schizophrenia, especially since many struggle with current treatments that either don't work well or have tough side effects.
ZLAB closed Monday's trading at $17.71, down $0.33 or 1.83 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.